Antiageing and Life Enhancement Pharmacotherapeutics

Publication Date	January 2006
Publisher	Spectra Intelligence
Product Type	Report
Pages	580
ISBN Number	not applicable
Product Code	SPE00009

Buy this product or for assistance call +44 20 7060 7474

PDF £795.00$1322 | €890

PRINT £825.00$1372 | €923

FAX Order above formats by FAX

Summary

Facets of normal chronological ageing and lifestyle contribute to a diverse group of highly prevalent conditions that are associated with physiological or psychological deficits or symptoms of sufficient severity which compel an individual to seek medical attention to restore, alter, or improve undesired aspects of body image, physical function, or wellbeing. The conditions are wide-ranging and comprise the four major medical specialty areas of dermatology, psychiatry, reproductive health and sexual disorders, which collectively include 10 major therapy areas, some of which are alopecia, cutaneous ageing, depressive illnesses, addictions, contraception, infertility, and erectile dysfunction.

Antiageing and life enhancement therapy areas are poised for dramatic expansion over the next decade driven by factors such as increasing worldwide ageing populations, unrelenting media fixation on physical improvement and restorative antiageing treatments, and innovation in the pharmaceutical industry to bring to market highly sophisticated efficacious drug treatments that serve to close the gap between medical and cosmetic interventions. Research and development investment in the specialty area is unfaltering with over 180 companies collectively investing more than US$5 billion in the hope to capitalize on a dynamic pipeline of 275 drug candidates that are currently progressing through to the clinic. Although the capital risks are high in the antiageing and life enhacement R&D arena, the potential returns on investment are vast in a market currently estimated at US$36 billion and predicted to rise to US$49 billion by 2012, and over US$100 billion by 2020.

New drug indications combined with next generation molecules and compounds will transform the landscape of how physicians treat disorders associated with ageing or lifestyle. Current drugs are being developed with multiple therapeutic benefits that will be able to treat several ailments through single dosing. Drugs on the horizon indicated for obesity, for example, also display secondary benefits for patients with coexisting diabetes and dyslipidaemia in addition to crossover indications for tobacco addiction. in this instance the interrelation of metabolic diseases can be improved by one drug alone as opposed to three potential drug medications, a facet that will revolutionize drug treatment regimens for patients, particularly those with high cardiovascular disease risk profiles where coexisting obesity, diabetes and smoking increase disease susceptibility. Moreover, novel drugs that alter body composition or effect changes in functional aspects of daily living are anticipated to not only change the armamentarium of medical treatments in the antiageing domain but also alter the 2006 Spectra Intelligence. All rights reserved.

medical perceptions of antiageing and life-enhancement treatments. Novel pharmacotherapeutics may redefine treatment paradigms allowing physicians the capacity to impede or rejuvenate internal physiological ageing mechanisms or halt deleterious effects caused by lifestyle activities. Pharmacological innovation in the field may even prove beneficial in the prevention of illnesses associated with traditional drug development areas, such as in musculoskeletal disease, cancer and neurodegenerative diseases due to therapeutic synergies and shared drug targets that underly salient pathophysiological mechanisms. in short, the antiageing and life enhancement specialty area is evolving into an exciting, innovative and highly dynamic discipline. Based on current trends, it is expected that the therapy areas will flourish offering a myriad of new drug treatment options for a range of conditions that are currently poorly served with high unmet needs.

in This Report Entitled Antiageing and Life Enhancement Pharmacotherapeutics:

Rejuvenating Drug Markets to 2012 and beyond, the reader will be introduced to a specialty pharmaceutical market that is transitioning to a high-growth, high-value prospect. The scope of the report encompasses up-to-date coverage of epidemiological, aetiological, and demographic data related to ageing and lifestyle disorders. Furthermore, market insights are provided by way of extensive sector analyses of marketed and newly launched products, pipeline drugs, and companyactivities, in addition to comment on strategic and commercial issues that may affect product positioning and revenue optimization. The report also discusses key prospects that have the potential to create new market sectors and become blockbuster products over the next decade.

Chapter 1 provides an overview of the antiageing and life enhancement domain and outlines the extent of the therapy areas and how they are categorized, classified, and characterized. This chapter also provides a comprehensive account of prevalence statistics, pathophysiology, treatment methods, and the types of pharmacotherapies currently available to combat symptoms of ageing and impairments that are related to lifestyle dysfunction.

An in-depth evaluation of dermatological conditions related to ageing and lifestyle is presented in Chapter 2. Therapy areas include alopecia, cutaneous ageing, pigmentation disorders, and the lipodermal areas of obesity and lipodystrophy. The chapter provides a detailed analysis of the sector to include insights for product extension and optimization, sales forecasts to 2012, and impact of late-stage pipeline 2006 Spectra Intelligence. All rights reserved. drugs on the market. Each therapy area segment concludes with a summary of the key issues that are considered to affect growth and sustainability.

Report Highlights and Key Findings

Data-intensive multipart tome on the state of the US$36bn antiageing and life enhancement drug market
in-depth market research and analysis of over 15 market sectors and subsectors
Comprehensive review of epidemiological, aetiological and therapeutic data for over 40 disorders
Sales estimates (US$) to 2012 for over 90 key products
Therapy forecasting for 10 specialty areas (US$)
Strategic insights for life-cycle optimization and product development
Evaluation of leading products and major competitors
Identified emerging growth markets with high-revenue yielding prospects
Recognized market drivers and inhibitors in the specialty pharma sector
Trend analysis of industry events and activities over the past 2 years
Detailed R&D themes and clusters by therapy area
Data generation on sector and market values between 2004-2012 and predictions to 2020 (US$)

Reasons to Purchase This Report

Qualitative assessment of current disorder characteristics, definitions, including aetiological and epidemiological data
Comprehensive update on antiageing and life enhancement drugs sector
in-depth analysis and discussion on the pathophysiology and prevalence of the main ageing and lifestyle disorders, including alopecia, cutaneous ageing, pigmentations conditions, obesity, depressive illnesses, addictions, sleep disorders, cognitive and memory impairments, contraception, infertility, and sexual disorders
Provides unrivalled insight into the development of antiageing and life enhancement drugs and emerging market opportunities
Market value predictions by therapy area and for individual marketed products to 2012
Quantitative analysis of marketed drugs and impact of new close-to-market candidates and pipeline products
Insight into potential blockbusters and super-blockbusters of the future
Illustrates the importance and need for antiageing and lifestyle medicines over the next 20 years
Provides extensive coverage of R&D pipelines of key players in the sector
Shows proprietary market modelling for prospect analysis across 15 main therapy areas.

What Can Be Learnt from This Report?

How are antiageing and lifestyle conditions defined and characterized?
What are the therapeutic benefits of antiageing and lifestyle drugs?
What are the main areas of antiageing and lifestyle drug development?
What criteria are involved in creating blockbuster antiageing and life enhancement drugs?
What is the impact of global ageing in lifestyle drug development?
What are the prevalence rates of ageing conditions and lifestyle disorders globally?
What factors are shaping the future of antiageing and lifestyle drug drug development?
What are the current market values for antiageing and life enhancement drugs and what will be the market value of this sector by 2012?
What are the emerging market opportunities for antiageing drugs?
What are the emerging market opportunities for life enhancement drugs?
Which therapeutic areas are identified for high-value growth?
Who are the main players in the antiageing and life enhancement domain?
Which companies are developing antiageing and life enhancement drugs?
Which antiageing and lifestyle drug development therapeutic areas are research intensive and which are not?
Which therapy areas are saturated and which represent niche market opportunities?
What is the future outlook for marketed antiageing and lifestyle drugs and for those in development?
What is the prediction for the global markets by 2020?
What are the top prospects in the development pipeline for antiageing and life enhancement therapy sectors?

Content

Chapter 1 Introduction to Antiageing and Life Enhancement Pharmacotherapeutics
- Ageing and Life Enhancement
- What are Antiageing and Life Enhancement Pharmacotherapeutics?
- Classifying the Ageing and Lifestyle Conditions
- Characteristics of Ageing and Lifestyle Conditions
- Categorizing Ageing and Lifestyle Conditions
- Marketed Antiageing and Life Enhancement Drugs
Ageing, Lifestyle Conditions, and Dermatology
- Alopecia
- Prevalence of Alopecia
- Alopecia as a Lifestyle Problem
- The Normal Hair Growth Cycle
- Types of Alopecia
- Dermal Ageing
- Photodamage and Solar Radiation
- Pollution and Dermal Damage
Dermal Pigmentation
- Hyerpigmentation and Hypopigmentation Disorders
- Biological Basis to Pigmentation: Melanogenesis and Photoprotection
- Cellular Mechanisms of Melanogenesis and Photoprotection
- Hyperpigmentation Disorders
- Hypopigmentation Disorders
- Vitiligo
- Albinism
- Postinflammatory Hypopigmentation
Lipodermal Disorders
- Gynoid Lipodystrophy
- The Development of Cellulite
- Treatments Options for Cellulite
- Obesity
- Obesity Prevalence
- Types of Obesity
- Measuring and Diagnosing Obesity
- Aetiological Aspects of Obesity
- Physiological Aspects of Hunger and Satiety
- Health Risks of Obesity
- Psychosocial Aspects of Obesity
Ageing, Life Enhancement, and the Central Nervous System
- Depression
- Prevalence
- Aetiology of Depression
- Types of Depression
- Major depression
- Dysthymia
- Bipolar Disorder
- Symptoms of Depression
- Anxiety Disorders
- Prevalence
Addiction Disorders
- Incidence of Addiction Disorders
- Neurobiological Basis of Addiction
- Treatment Options
Cognitive/Memory Deficits
- Prevalence
- Pharmacotherapy for Cognitive Impairment
Sleep Disorders
- Insomnia
- Prevalence of Insomnia
- Causes of Insomnia
- Restless Legs Syndrome
- Prevalence of Restless Legs Syndrome
- Circadian Rhythm Sleep Disorders
- Delayed Sleep Disorders
- Shift-Work Sleep Disorder
- Jet-Lag Sleep Disorders
- Excessive Daytime Sleepiness and Narcolepsy
- Narcolepsy
- Prevalence of Narcolepsy
- Neurobiological Basis to Narcolepsy
- Treatments for Narcolepsy
- Sleep Apnoea
- Obstructive Sleep Apnoea
- Prevalence of Obstructive Sleep Apnoea
- Therapeutics for Sleep Apnoea
Ageing, Lifestyle Conditions, and Reproductive Health
- Elective Infertility - Contraception
- The Birth of Contraception
- Inducing Infertility via Ovulation Suppression
- Combined Oral Contraceptives
- Fertility Disorders
- Assisted Conception
Ageing, Lifestyle Conditions, and Urology
- Sexual Disorders
- Prevalence of Sexual Dysfunction
- Male Sexual Disorders
- Sexual Desire Disorders
- Male Erectile Dysfunction
- Normal Erectile Function
- Psychological Aspects of Male Erectile Dysfunction
- Prevalence of Male Erectile Dysfunction
- Therapeutics for Male Erectile Dysfunction
- Priapism
- Peyronie's disease
- Disorders of Ejaculation
- Premature Ejaculation
- Retarded Ejaculation
- Retrograde Ejaculation
Female Sexual Dysfunction
- Prevalence of Female Sexual Dysfunction
- Specific Female Sexual Dysfunction Disorders
- Disorders of Desire
- Disorders of Arousal
- Disorders of Lubrication
- Persistent Sexual Arousal Syndrome
- Disorders of Orgasm
- Pain Disorders
- Dyspareunia
- Vulvodynia
- Vaginismus
Chapter 2 Dermatology
- Alopecia
- Alopecia Drug Market Overview
- Market Forecasts for Alopecia Products
- Market Analysis for the Alopecia Drug Market
- Propecia (Finasteride) - Merck
- Rogaine/Regaine (Minoxidil) - Pfizer
- Product Extension Strategy Insights for Alopecia Products
- Product Extension Strategy Insights for Finasteride
- Product Extension Strategy Insights for Minoxidil
- Future Considerations for Drugs to Treat Alopecia
- Drug Development Prospects
- BIO024 - Genaderm
- Other Clinical Candidates
Cutaneous Ageing
- Dermal Ageing Product Market Overview
- Market Forecasts for Dermal Ageing Products
- Market Analysis for Cutaneous Ageing/Photodamage Products
- Market Insights and Strategies for the Botulinum Toxin Sector
- Direct Competition to Botox
- Botulinum Toxin Products in Asia and South America
- Product Extension Strategy Insights for Botulinum Toxin Products
- Market Insights and Strategies for the Topical Antiageing Product Sector
- Product Extension Strategy Insights for Topical Antiageing Products
- Tretinoin
- Isotretinoin
- Tazarotene
- Idebenone
- Acid Peel Products
- Future Considerations and Market Insights for the Cutaneous Antiageing
- Product Sector
Dermal Pigmentation Conditions
- Market Forecasts for Dermal Pigmentation Products
- Market Analysis of the Dermal Pigmentation Product Sector
- Market Insights and Potential Product Development Strategies for Hyperpigmentation
- Conditions
- Hydroquinone
- Tretinoin
- Azelaic Acid
- Market Insights and Potential Product Development Strategies for Hypopigmentation
- Conditions
- Induced Photoprotective Melanogenesis
- Therapeutic, Prophylactic, and Cosmetic Markets for Photoprotective Melanogenesis
- Solar Allergies/Polymorphous Light Eruption
- Other Hypopigmentation Conditions
- Skin Cancer Prophylaxis
- Cosmetic-Medical Indications
- Future Considerations and Market Outlook for the Dermal Pigmentation Therapy Area
Lipodermal Conditions
- Gynoid Lipodystrophy (Cellulite)
- Novel Pharmacotherapeutics for Cellulite
- BIO303 - Enhance Biotech/Bioaccelerate
- Phosphatidylcholine (Lecithin)
- Redeveloping Old Molecules for New Cosmetic Indications
- Obesity
- Market Analysis for Antiobesity Drugs
- Market Forecasts for Antiobesity Drugs
- Antiobesity Product Extension Strategies and Insights
- Sibutramine - (Meridia/Reductil) Abbot Laboratories
- Market Outlook for Sibutramine
- Orlistat
- Class Competition - ATL-962 (Cetilistat) Alizyme
- Product Extension Strategy Insights for Orlistat
- Antiobesity Drugs at the Premarket Authorization Stage
- Rimonabant
- Safety and Efficacy Data
- Lipodermal Disorders - Future Considerations and Market Insights
- New Weight Regulation and Lipid Metabolism Market Opportunities
Chapter 3 Central Nervous System/Psychiatry
- Psychological Disorders: Depression and Anxiety
- Market Overview of Drugs to Treat Depression and Anxiety Disorders
- Market Analysis and Insights for Drugs to Treat Depressive Illnesses
- Market Analysis: Antidepressant Therapy Area
- Prozac (Fluoxetine) - Eli Lilly
- Product Overview
- Indications and Supplementary Labelling
- Patent Expiry and Reformulation
- Sales Prospects
- Commercial Outlook
- Cymbalta (Duloxetine) - Eli Lilly/Boehringer Ingelheim
- Product Overview
- Indications and Supplementary Labelling
- Sales Prospects
- Commercial Outlook
- Zoloft/Lustral (Sertraline) - Pfizer
- Product Overview
- Indications and Supplementary Labelling
- Patent Expiry and Reformulation
- Sales Prospects
- Commercial Outlook
- Seroxat/Paxil/Deroxat (Paroxetine) - GlaxoSmithKline
- Product Overview
- Indications and Supplementary Labelling
- Patent Expiry and Reformulation
- Sales Prospects
- Commercial Outlook
- Wellbutrin (Bupropion) - GlaxoSmithKline
- Product Overview
- Indications and Supplementary Labelling
- Patent Expiry and Reformulation
- Sales Prospects
- Commercial Outlook
- Effexor (Venlafaxine) - Wyeth
- Product Overview
- Indications and Supplementary Labelling
- Patent Expiry and Reformulation
- Sales Prospects
- Commercial Outlook
- Remeron/Zispin (Mirtazapine) - Organon/Akzo Nobel
- Product Overview
- Indications and Supplementary Labelling
- Patent Expiry and Reformulation
- Sales Prospects
- Commercial Outlook
- Cipramil/Celexa (Citalopram) - Lundbeck/Forest Laboratories
- Product Overview
- Indications and Supplementary Labelling
- Patent Expiry and Reformulation
- Sales Prospects
- Commercial Outlook
- Cipralex/Lexapro (Escitalopram) - Lundbeck/Forest
- Product Overview
- Indications and Supplementary Labelling
- Patent Expiry and Reformulation
- Sales Prospects
- Commercial Outlook
- Future Considerations and Market Insights for the Antidepressant Market
- Pipeline Antidepressants
- Pipeline Focus
- Valdoxan (Agomelatine) - Servier
Pharmacotherapeutics for Cognitive/Memory Deficits
- Future Market Focus - Age-Related Cognitive Decline
- Companies Developing Drugs for Memory and Cognitive Enhancement
Behavioural Disorders: Addictions
- Market Overview for Addiction Disorders
- Market Forecasts by Therapeutic Area
- Alcohol Addiction
- Narcotic Addiction
- Tobacco Addiction
- Market Forecasts for Addiction Disorders
- Market Analysis of Drugs to Treat Addiction Disorders
- Alcohol Addiction
- Alcohol Addiction Pharmacotherapies
- Acamprosate (Campral) - Merck/Forest Laboratories
- Mechanisms of Action/Efficacy
- Sales Estimates for Campral
- Product Line Extension Possibilities
- Disulfiram (Antabuse) - Alpharma
- Mechanism of Action/Efficacy
- Sales Estimates for Disulfiram
- Naltrexone Hydrochlride
- Mechanisms of Action/Efficacy
- Reformulation - Vivitrol, Alkermes/Cephalon
- Sales Estimates for Naltrexone
- Pipeline Focus
- Naltrexone Depot - Drug Abuse Sciences, France
- Nalmefene - BioTie Therapies, Finland
- Alcohol Addiction - Market Insights and Future Considerations
- Narcotic Addiction Pharmacotherapeutics
- Cocaine Addiction
- Mechanisms of Action of Cocaine
- Future Therapeutics for Cocaine Addiction
- Vaccine Therapy Focus - Xenova
- COC-AB/DAS-431 - Drug Abuse Sciences
- Opiate Addiction
- Drug Substitute Therapies
- Subutex/Subroxone (Buprenorphine) - Schering-Plough/Reckitt Benckiser
- Mechanisms of Action/Efficacy
- Reformulation
- Sales Estimates
- Methadone
- Mechanisms of Action/Efficacy
- Sales Estimates
- Drugs to Control Opiate Withdrawal Symptoms
- Brittofex (Lofexidine) - Britannia Pharmaceuticals
- Mechanisms of Action/Efficacy
- Sales Estimates
- Naltrexone
- Potential Reformulation
- Future Drugs to Treat Opiate Addiction
- Probuphine - Titan Pharmaceuticals
- Buprenorphine Depot - Drug Abuse Sciences
- Narcotic Addiction - Market Insights and Future Considerations
- Emerging Drug Addiction Focus
- Methamphetamine/Phencyclidine Abuse and Dependency
- InterveXion Therapeutics
- Outlook for Pharmacotherapeutic Markets Related to Alcohol and
- Substance Abuse
- Smoking Addiction
- Prevalence and Mortality Statistics
- Nicotine - Mechanism of Action
- Nicotine Dependency and Smoking Cessation
- Smoking and Health Consequences
- Healthcare Costs of Smoking Addiction
- Smoking Addiction Pharmacotherapeutics
- Market Analysis of Smoking Cessation Pharmacotherapeutics
- Nicotine Replacement Therapies
- Nicorette/Nicotrol - Pfizer
- Sales Estimates
- NiQuitin/NicoDerm/Nicorette/Nicabate - GlaxoSmithKline
- Sales Estimates
- Nicotinell/Habitrol - Novartis
- Sales Estimates
- Other Smoking Cessation Pharmacotherapies
- Zyban (Bupropion) - GlaxoSmithKline
- Sales Estimates
- Future Drugs to Treat Smoking Addiction
- Late-Stage Development Product Focus
- Rimonabant (Acomplia) - Sanofi-Aventis
- Varenicline - Pfizer
- Vaccine Focus
- NicVAX - Nabi Biopharmaceuticals
- TA-NIC - Xenova
- Smoking Addiction - Market Insights and Future Considerations
- Drugs in the Pipe
Behavioural/CNS: Sleep Disorders
- Market Overview for Sleep Disorders
- Insomnia
- Wake-Promotion
- Restless Legs Syndrome
- Market Analysis for Drugs to Treat Sleep Disorders
Insomnia
- Market Analysis for the Insomnia Pharmacotherapies
- Key Insomnia Drugs
- Ambien/Stilnox/Stilnoct/Myslee (Zolpidem) - Sanofi-Aventis
- Mechanism of Action
- Efficacy
- Reformulation
- Sales Estimates
- Commercial Outlook
- Halcion (Triazolam) - Pfizer
- Mechanism of Action
- Reformulation
- Sales Estimates
- Commercial Outlook
- Lunesta (Eszopiclone) - Sepracor
- Mechanism of Action
- Sales Estimates
- Commercial Outlook
- Rozerem (Ramelteon) - Takeda Pharmaceuticals
- Mechanism of Action
- Efficacy
- Sales Estimates
- Commercial Outlook
- Sonata (Zaleplon) - Wyeth/King Pharmaceuticals
- Mechanism of Action
- Efficacy
- Reformulation
- Sales Estimates
- Commercial Outlook
- Premarket Focus - Late-Stage Development Drugs for Insomnia
- Indiplon - Neurocrine Biosciences/Pfizer
- Mechanisms of Action
- Formulation Development
- Efficacy
- Commercial Prospects
- Gaboxadol - Lundbeck/Merck & Co
- Mechanisms of Action
- Efficacy
- Commercial Prospects
- Other Pipeline Drug Candidates for Insomnia
- Silenor (Doxepin) - Somaxon Pharmaceuticals
- Posidorm - Alliance Pharma
- Future Considerations and Market Outlook for the Insomnia Drug Market
Wake-Promotion
- Narcolepsy/Excessive Daytime Sleepiness
- Market Analysis for Key Drugs for Narcolepy/Excessive Daytime Sleepiness
- Provigil (Modafanil) - Cephalon
- Mechanism of Action
- Efficacy
- Supplementary Indications
- Reformulation
- Sales Estimates
- Commercial Prospects
- Xyrem (Sodium oxybate) - Orphan Medical/Jazz Pharmaceuticals
- Efficacy
- Side Effects
- Sales Estimates
- Commerical Prospects
- Future Considerations and Market Outlook for Wake-Promoting Drugs
Restless Legs Syndrome
- Requip/Adartrel/Repreve (Ropinirole) - GlaxoSmithKline
- Mechanisms of Action
- Efficacy
- Sales Estimates
- Commercial Outlook
- Drugs in Development for Restless Legs Syndrome
- Premarket Focus: Pramipexole - Boehringer Ingelheim
- Efficacy
- Commerical Prospects
Sleep Apnoea - An Emerging High-Growth Sector
- Obstructive Sleep Apnoea-Hyponoea Syndrome - An Underdiagnosed
- Problem
- Commercial Insights
- Pipeline Focus
- Future Considerations and Market Insights for Drugs to Treat Sleep
- Disorders
Chapter 4 Reproductive Health: Contraception and Infertility
- Reproductive Health Market Overview
- Market Analysis for Contraception and Infertility
- Infertility
- Hormonal Contraception
- Contraceptive Formulations
- Combined Oestrogen-Progestogen Contraceptives
- Progestogen-Only Contraceptives
Product Market for Hormonal Contraceptives
- Janssen-Cilag/Ortho-McNeil/Johnson & Johnson
- Key Product and Portfolio Review
- Sales Estimates and Product Market Outlook
- Organon/Akzo Nobel
- Key Product and Portfolio Review
- Pipeline Focus
- EMM 310066
- Male Contraception - Organon/Schering
- Sales Estimates and Product Market Outlook
- Pharmacia/Pfizer
- Key Product and Portfolio Review
- Sales Estimates and Product Market Outlook
- Schering/Berlex
- Key Product and Portfolio Review
- Pipeline Focus
- Yaz
- Contraceptive Patch
- E2/DNG Pill
- Male Contraception
- Sales Estimates and Product Market Outlook
- Wyeth
- Key Product and Portfolio Review
- Sales Estimates and Product Market Outlook
- Barr Laboratories
- Key Product and Portfolio Review
- Pipeline Focus
- Sales Estimates and Product Market Outlook
- Contraceptives in Research and Development
- Future Considerations and Outlook for the Contraceptive Product Market
Infertility Pharmacotherapeutics
- Market Overview for Infertility Drugs
- Pharmacotherapies for Infertility
- Mechanism of Action of Infertility Pharmacotherapeutics
- Product Market Analysis for Infertility Pharmacotherapeutics
- AstraZeneca
- Key Product and Portfolio Review
- Sales Estimates and Product Market Outlook
- Ferring
- Key Product and Portfolio Review
- Pipeline Focus
- Sales Estimates and Product Market Outlook
- Organon
- Key Product and Portfolio Review
- Pipeline Focus
- Sales Estimates and Product Market Outlook
- Serono
- Key Product and Portfolio Review
- Pipeline Focus
- Sales Estimates and Product Market Outlook
- Future Considerations and Market Insights for Infertility Pharmacotherapeutics
- Infertility Drugs in Research and Development
- Novel Female Infertility Pharmacotherapeutics
- Novel Male Infertility Pharmacotherapeutics
Chapter 5 Urology: Sexual Disorders
- Sexual Disorders Market Overview
- Market Analysis for Sexual Disorder Pharmacotherapeutics
- Testosterone Replacement
- Erectile Dysfunction
- Female Sexual Disorders
Male Sexual Disorders
- Androgen Deficiency and Disorders of Desire
- The Andropause
- Product Market Analysis for Androgen Deficiency and Disorders of Desire
- Columbia Labs/Ardana
- Sales Estimates and Market Outlook
- Organon
- Sales Estimates and Market Outlook
- Schering
- Sales Estimates and Market Outlook
- Solvay Pharmaceuticals
- Sales Estimates and Market Outlook
- Drugs in Research and Development for Androgen Deficiency and Andropause
- Future Considerations for Drugs to Treat Androgen Deficiencies Associated
- with Sexual Disorders and Andropause
Male Erectile Dysfunction
- Uprima/Ixense (Apomorphine) - Abbott/TAP Pharmaceuticals
- Sales Estimates and Market Outlook
- Levitra (vardenafil) - Bayer/GlaxoSmithKline
- Sales Estimates and Market Outlook
- Cialis (tadalafil) - Lilly/ICOS
- Sales Estimates and Market Outlook
- Viagra (Sildenafil); Caverject (Alprostadil) - Pharmacia/Pfizer
- Sales Estimates and Market Outlook
- Viridal/Edex (Alprostadil) - Schwarz
- Sales Estimates and Market Outlook
- Invicorp (Phentolamine Mesilate/Vasoactive Intestinal Polypeptide) -
- Senetek/Ardana
- Sales Estimates and Market Outlook
- MUSE (Alprostadil) - Vivus
- Sales Estimates and Market Outlook
- Pipeline Focus - Avanafil
- Future Considerations and Market Outlook for Drugs to Treat
- Erectile Dysfunction
- Pipeline Drugs and Market Prospects in the Sexual Disorder Market
- Erectile Dysfunction Drug Pipeline
Emerging Sexual Disorder Therapy Areas
- Premature Ejaculation
- Neuronal Mechanism of Premature Ejaculation
- Drugs in Development for Premature Ejaculation
- Future Considerations and Market Outlook for Drugs to Treat
- Premature Ejaculation
Female Sexual Disorders
- An High-Growth Market Opportunity?
- Drugs in Development for Female Sexual Disorders
- Future Considerations and Market Outlook for Drugs to Treat
- Female Sexual Dysfunction
Chapter 6 Drugs in Research and Development
- Introduction
Dermatology
- Alopecia
- Research and Development Overview
- Dermal Ageing
- Research and Development Overview
- Pigmentation Conditions
- Research and Development Overview
- Lipodermal Conditions
- Obesity
- Research and Development Overview
Central Nervous System/Psychiatry
- Psychological Disorders: Depression and Anxiety
- Research and Development Overview
- Psychological Disorders: Cognitive/Memory Impairments
- Research and Development Overview
- Behavioural Disorders: Addictions
- Research and Development Overview
- Sleep Disorders
- Research and Development Overview
Reproductive Health: Contraception and Infertility
- Contraception
- Research and Development Overview
- Infertility
- Research and Development Overview
Sexual Disorders
- Male Sexual Disorders
- Research and Development Overview
- Female Sexual Dysfunction
- Research and Development Overview
Chapter 7 Market Analysis, Therapy Forecasting, and Prospect Mining
- Introduction: Data Analysis, Therapy Forecasting, and Prospect Mining
- The Antiageing and Life Enhancement Pharmacotherapeutics Market
- Market Growth in the Antiageing and Life Enhancement Dug Market
- Subsector Data Analysis
- Market Analysis and Therapy Forecasting
- Dermatology: Alopecia, Dermal Ageing, Pigmentation Disorders and
- Lipodermal Conditions
- Therapy Area Forecasts
- Market Share of Dermatological Therapy Areas
- CNS/Psychiatry: Depression/Anxiety, Addictions, and Sleep-Wake Disorders
- Therapy Area Forecasts
- Market Share of CNS Therapy Areas
- Reproductive Medicine: Contraception and Infertility
- Therapy Area Forecasts
- Market Share of Reproductive Medicine Therapy Areas
- Urology: Sexual Disorders
- Therapy Area Forecasts
- Market Share of Male Sexual Disorder Market
Comparative Analysis: Product Sales
- Dermatology Therapy Areas
- CNS Therapy Areas
- Reproductive Medicine Therapy Areas
- Urology: Sexual Disorder Therapy Areas
Prospect Mining
- Dermatological Drug Prospects in the Antiageing and Life Enhancement
- Therapy Market
- Alopecia
- Dermal Ageing
- Dermal Pigmentation
- Lipodermal Conditions
- Central Nervous System Drug Prospects in the Antiageing and Life Enhancement
- Therapy Market
- Depression and Anxiety
- Cognitive/Memory Impairment
- Addictions
- Sleep Disorders
- Reproductive Health Drug Prospects in the Antiageing and Life Enhancement
- Therapy Market
- Contraception
- Infertility
- Sexual Disorder Drug Prospects in the Antiageing and Life Enhancement
- Therapy Market
- Androgen Deficiency/Testosterone Replacement
- Erectile Dysfunction and Premature Ejaculation
- Female Sexual Disorders
- Top Prospects in the Antiageing and Life Enhancement Therapy Market
- Novel Indications
- Therapy Area Forecasts 2012 and 2020
Chapter 8 Report Synopsis
- Dermatology
- Alopecia - Key Data Points
- Dermal Ageing and Pigmentation Disorders - Key Data Points
- Lipodermal Conditions - Key Data Points
- Central Nervous System
- Depression/Anxiety and Cognitive Impairment - Key Data Points
- Addictions - Key Data Points
- Sleep Disorders and Wake Promotion - Key Data Points
- Reproductive Health
- Contraception Data - Key Data Points
- Infertility - Key Data Points
- Sexual Disorders
- Male Sexual Disorders - Key Data Points
- Female Sexual Disorders - Key Data Points
- The Antiageing and Life Enhancement Drug Market
- Key Market Data Points
Glossary and Abbreviations
Bibliography and Reference Sources
List of Tables
- Table 1.1 Characteristics Related to Ageing and Lifestyle Conditions
- Table 1.2 Ageing and Lifestyle Conditions Categorized by Medical Specialty
- Table 1.3 Marketed Antiageing and Life Enhancement Drugs, 2005
- Table 1.4 Types of Alopecia
- Table 1.5 Features of Intrinsic Chronological Cutaneous Ageing and Photoageing
- Table 1.6 Factors Associated with Dermal Ageing
- Table 1.7 Types of Solar Radiation
- Table 1.8 Common Hyperpigmentation Disorders
- Table 1.9 Types of Hypopigmentation Disorders
- Table 1.10 Calculating Body Mass Index
- Table 1.11 Aetiological Factors Associated with Obesity
- Table 1.12 Health Risks and Comorbidities Associated with Obesity
- Table 1.13 Psychological, Behavioural, and Socioenvironmental Factors Associated with Obesity
- Table 1.14 Role of Neurotransmitters in Depression
- Table 1.15 Symptoms of Depression and Bipolar Disorder/Mania
- Table 1.16 Major Anxiety Disorders
- Table 1.17 Neurotransmitter Systems Associated with Addiction
- Table 1.18 Drugs of Abuse and their Associations with Neurotransmitter Systems
- Table 1.19 Causes of Dementia
- Table 1.20 Insomnia Categorized by Duration of Symptoms
- Table 1.21 Causes of Insomnia
- Table 1.22 Symptoms of Narcolepsy
- Table 1.23 Medical and Surgical Treatment Options for Sleep Apnoea
- Table 1.24 Global Prevalence Rates of Oral Contraceptive Use
- Table 1.25 Popular Combined Oral Contraceptives, 2005
- Table 1.26 Biological Causes of Infertility
- Table 1.27 Assisted Conception Techniques
- Table 1.28 Male and Female Sexual Dysfunction Disorders
- Table 1.29 Medical and Surgical Conditions Associated with Erectile Dysfunction
- Table 1.30 Therapeutic Options for Male Erectile Dysfunction, 2005
- Table 2.1 Estimated Global Sales & Forecasts of Drugs for Alopecia (US$m), 2004-2012
- Table 2.2 Estimated Global Sales & Forecasts of Dermal Antiageing Products, 2004-2012
- Table 2.3 Topical Antiageing/Photodamage Products, 2005
- Table 2.4 Estimated Global Sales & Forecasts of Products for Pigmentation Conditions, 2004-2012
- Table 2.5 Pharmaceutical Products to Treat Common Dermal Pigmentation, 2005
- Table 2.6 Estimated Global Sales & Forecasts of Antiobesity Drugs, 2004-2012
- Table 3.1 Estimated Global Sales & Forecasts of Leading Antidepressants, 2004-2012
- Table 3.2 Estimated Annual Growth Rates of Leading Antidepressants (%), 2004-2012
- Table 3.3 Leading Antidepressants Ranked by Sales, 2005 & 2012 (est.)
- Table 3.4 Primary and Secondary Indications for Antidepressants
- Table 3.5 Estimated Sales (US$) and Annual Growth (%) of Prozac, 2005-2012
- Table 3.6 Estimated Sales (US$) and Annual Growth (%) of Cymbalta, 2005-2012
- Table 3.7 Estimated Sales (US$) and Annual Growth (%) of Zoloft, 2005-2012
- Table 3.8 Estimated Sales (US$) and Annual Growth (%) of Seroxat/Paxil, 2005-2012
- Table 3.9 Estimated Sales (US$) and Annual Growth (%) of Wellbutrin, 2005-2012
- Table 3.10 Estimated Sales (US$) and Annual Growth (%) of Effexor, 2005-2012
- Table 3.11 Estimated Sales (US$) and Annual Growth (%) of Remeron, 2005-2012
- Table 3.12 Estimated Sales (US$) and Annual Growth (%) of Cipramil/Celexa, 2005-12
- Table 3.13 Estimated Sales (US$) and Annual Growth (%) of Cipralex/Lexapro, 2005-12
- Table 3.14 Drugs in Development for Cognitive and Memory Impairment, 2005
- Table 3.15 Estimated Global Sales, Forecasts, and Growth of Key Drugs to Treat Addictions, 2004-2012
- Table 3.16 Physiological Consequences of the Disulfiram-Alcohol Reaction
- Table 3.17 Estimated Sales and Annual Percentage Growth of Smoking Cessation Therapies, 2004-2012
- Table 3.18 Drugs in Development for Smoking Cessation, 2005
- Table 3.19 Estimated Global Sales & Forecasts of Leading Drugs for Sleep Disorders, 2004-2012
- Table 3.20 Marketed Drugs to Treat Insomnia, 2005
- Table 3.21 Drugs in Development for Restless Legs Syndrome, 2005
- Table 4.1 Estimated Global Sales & Forecasts of Leading Hormonal Contraceptives and Infertility Drugs, 2004-2012
- Table 4.2 Selection of Contraceptives Segmented by Formulation and Delivery Route, 2005
- Table 4.3 Johnson & Johnson's Hormonal Contraceptive Product Portfolio, 2005
- Table 4.4 Estimated Sales (US$) and Annual Growth (%) of Ortho-McNeil/ Johnson & Johnson's Hormonal Contraceptive Portfolio, 2005-2012
- Table 4.5 Organon/Akzo Nobel's Hormonal Contraceptive Product Portfolio, 2005
- Table 4.6 Estimated Sales (US$) and Annual Growth (%) of Organon/Akzo Nobel's Hormonal Contraceptive Portfolio, 2005-2012
- Table 4.7 Pfizer's Hormonal Contraceptive Product Portfolio, 2005
- Table 4.8 Estimated Sales (US$) and Annual Growth (%) of Pfizer's Hormonal Contraceptive Portfolio, 2005-2012
- Table 4.9 Schering/Berlex' Hormonal Contraceptive Product Portfolio, 2005
- Table 4.10 Schering/Berlex' Pipeline Contraceptive Candidates, 2005
- Table 4.11 Estimated Sales (US$) and Annual Growth (%) of Schering/Berlex' Hormonal Contraceptive Portfolio, 2005-2012
- Table 4.12 Wyeth's Hormonal Contraceptive Product Portfolio, 2005
- Table 4.13 Estimated Sales (US$) and Annual Growth (%) of Wyeth's Hormonal Contraceptive Portfolio, 2005-2012
- Table 4.14 Barr's Hormonal Contraceptive Product Portfolio, 2005
- Table 4.15 Estimated Sales (US$) and Annual Growth (%) of Barr's Hormonal 357Contraceptive Portfolio, 2005-2012
- Table 4.16 Pipeline Hormonal Contraceptives, 2005
- Table 4.17 Pharmacotherapies for Infertility, 2005
- Table 4.18 AstraZeneca's Hormonal Infertility Product Portfolio, 2005
- Table 4.19 Estimated Global Sales (US$) and Annual Growth (%) of AstraZeneca's Hormonal Infertility Products, 2005-2012
- Table 4.20 Ferring's Infertility Product Portfolio, 2005
- Table 4.21 Estimated Global Sales (US$) and Annual Growth (%) of Ferring's Infertility Products, 2005-2012
- Table 4.22 Organon's Hormonal Infertility Product Portfolio, 2005
- Table 4.23 Estimated Global Sales (US$) and Annual Growth (%) of Organon's Hormonal Infertility Products, 2005-2012
- Table 4.24 Serono's Hormonal Infertility Product Portfolio, 2005
- Table 4.25 Estimated Global Sales (US$) and Annual Growth (%) of Serono's Hormonal Infertility Products, 2005-2012
- Table 4.26 Drugs in Research and Development for Infertility, 2005-11-15
- Table 5.1 Global Sales & Forecasts of Leading Drugs for Male Sexual Disorders, 2004-2012
- Table 5.2 Marketed Drugs for Androgen Deficiency and Male Erectile Dysfunction, 2005
- Table 5.3 Symptoms of Andropause
- Table 5.4 Estimated Sales (US$) and Annual Growth (%) of Striant, 2005-2012
- Table 5.5 Estimated Sales (US$) and Annual Growth (%) of Organon's Androgen Replacement Therapy Products, 2005-2012
- Table 5.6 Estimated Sales (US$) and Annual Growth (%) of Schering's Andrology Product Portfolio, 2005-2012
- Table 5.7 Estimated Sales (US$) and Annual Growth (%) of Androgel, 2005-2012
- Table 5.8 Drugs in Development for Androgen Deficiency and Andropause, 2005
- Table 5.9 Estimated Sales (US$) and Annual Growth (%) of Uprima/Ixense, 2005-2012
- Table 5.10 Estimated Sales (US$) and Annual Growth (%) of Levitra, 2005-2012
- Table 5.11 Estimated Sales (US$) and Annual Growth (%) of Cialis, 2005-2012
- Table 5.12 Estimated Sales (US$) and Annual Growth (%) of Pfizer's Erectile Dysfunction Product Portfolio, 2005-2012
- Table 5.13 Estimated Sales (US$) and Annual Growth (%) of Viridal/Edex, 2005-2012
- Table 5.14 Estimated Sales (US$) and Annual Growth (%) of Invicorp, 2005-2012
- Table 5.15 Estimated Sales (US$) and Annual Growth (%) of Muse, 2005-2012
- Table 5.16 Drugs in Development for Male Erectile Dysfunction, 2005
- Table 5.17 Drugs in Development for Premature Ejaculation, 2005
- Table 5.18 Drugs in Development for Female Sexual Dysfunction, 2005
- Table 6.1 Drugs in Development for Alopecia, 2005
- Table 6.2 Drugs in Development for Dermal Ageing, 2005
- Table 6.3 Drugs in Development for Pigmentation Disorders, 2005
- Table 6.4 Drugs in Development for Gynoid Lipodystrophy (Cellulite), 2005
- Table 6.5 Drugs in Development for Obesity, 2005
- Table 6.6 Drugs in Development for Appetite Stimulation and Lipodystrophy, 2005
- Table 6.7 Drugs in Development for Depression and Anxiety, 2005
- Table 6.8 Drugs in Development for Cognitive and Memory Impairment, 2005
- Table 6.9 Drugs in Development for Alcohol and Narcotic Addictions, 2005
- Table 6.10 Drugs in Development for Nicotine Addiction, 2005
- Table 6.11 Drugs in Development for Sleep Disorders, 2005
- Table 6.12 Female Oral Contraceptives in Development, 2005
- Table 6.13 Nonoral Female Contraceptives in Development, 2005
- Table 6.14 Male Contraceptives in Development, 2005
- Table 6.15 Drugs in Development for Infertility, 2005
- Table 6.16 Drugs in Development for Male Androgen Deficiency and Andropause, 2005
- Table 6.17 Drugs in Development for Male Erectile Dysfunction and Premature Ejaculation, 2005
- Table 6.18 Drugs in Development for Female Sexual Dysfunction, 2005
- Table 7.1 World Market for Antiageing and Life Enhancement Drugs (US$m), 2004-2012
- Table 7.2 Antiageing and Life Enhancement Therapy Areas Ranked by Market Share, 2005 & 2012
- Table 7.3 Global Drug Market for Dermatological Conditions Associated with Ageing and Lifestyle Dysfunction (US$m), 2004-2012
- Table 7.4 Global Drug Market for CNS Conditions Associated with Ageing and Lifestyle Dysfunction (US$m), 2004-2012
- Table 7.5 Global Drug Market for Hormonal Contraception and Infertility (US$m), 2004-2012
- Table 7.6 Global Market for Male Sexual Disorders (US$m), 2004-2012
- Table 7.7 Novel Indications in the Antiageing and Life Enhancement Therapy Drug Market, 2005
- Table 7.8 Therapy Area Forecasts for the Global Antiageing and Life Enhancement Drug Market, 2012 and 2020
List of Figures
- Figure 1.1 Factors Associated with Ageing and Lifestyle Conditions
- Figure 1.2 Factors Involved in Normal Body Weight Regulation
- Figure 1.3 Prevalence of Alcohol, Smoking, and Illicit Drug Abuse in UK and US Populations, 2002-2004
- Figure 1.4 Lifestyle Disorder Characteristics Associated with Contraception
- Figure 1.5 Lifestyle Factors Affecting Fertility
- Figure 2.1 Projected Growth Rates for Alopecia Drugs, 2005-2012
- Figure 2.2 Estimated Global Sales of Alopecia Drugs, 2004-2012
- Figure 2.3 Projected Growth Rates for Cutaneous Antiageing Products, 2005 & 2012
- Figure 2.4 Estimated Global Sales of Dermal Antiageing Products, 2004-2012
- Figure 2.5 Projected Growth Rates of Products for Pigmentation Conditions, 2005 & 2012
- Figure 2.6 Estimated Global Sales of Products for Pigmentation Conditions, 2004-2012
- Figure 2.7 Projected Growth Rates of Current Antiobesity Drugs, 2005-2012
- Figure 2.8 Estimated Global Sales of Antiobesity Drugs, 2004-2012 172
- Figure 2.9 Main Drivers of Growth in the Antiobesity Pharmacotherapeutic Market
- Figure 3.1 Estimated Global Sales of Leading Antidepressants, 2005 & 2012
- Figure 3.2 Estimated Market Share of Leading Antidepressants, 2005 & 2012
- Figure 3.3 Estimated Sales of Addiction Drugs Segmented by Therapeutic Area, 2004-2012
- Figure 3.4 Estimated Global Sales of Leading Addiction Drugs by Therapy Area, 2005 & 2012
- Figure 3.5 Estimated Sales and Forecasts of Sleep Disorder Drugs Segmented by Therapeutic Area, 2004-2012
- Figure 3.6 Estimated Global Market Share of Sleep Disorder Drugs by Therapy Area, 2005 & 2012
- Figure 4.1 Estimated Sales and Forecasts of Hormonal Contraceptives and Infertility Drug Sectors, 2004-2012
- Figure 4.2 Estimated Global Market Share for Hormonal Contraceptives and Infertility Drug Sectors, 2005 & 2012
- Figure 5.1 Estimated Sales and Forecasts of Leading Drugs for Male Sexual Disorders, 2004-2012
- Figure 5.2 Global Market Share of Leading Drugs for Male Sexual Disorders, 2005 & 2012
- Figure 7.1 Antiageing and Life Enhancement Market Segmented by Specialty Area, 2005 & 2012
- Figure 7.2 Annual Growth Rates of Antiageing and Life Enhancement Drug Therapy Specialty Areas Between 2005 and 2012
- Figure 7.3 Antiageing and Life Enhancement Market Segmented by Therapy Area, 2005 & 2012
- Figure 7.4 Dermatological Therapy Area Forecasts, 2005 & 2012 (US$m)
- Figure 7.5 Market Share of Dermatological Therapy Areas, 2005 & 2012
- Figure 7.6 CNS Therapy Area Forecasts, 2005 & 2012 (US$m)
- Figure 7.7 Market Share of CNS Therapy Areas, 2005 & 2012
- Figure 7.8 Hormonal Contraceptive and Infertility Therapy Area Forecasts, 2005 & 2012 (US$m)
- Figure 7.9 Market Share of Hormonal Contraception and Infertility Therapy Areas, 2005 & 2012
- Figure 7.10 Therapy Area Forecasts for Male Testosterone Replacement and Erectile Dysfunction, 2005 & 2012 (US$m)
- Figure 7.11 Market Share of Male Testosterone Replacement (Desire/Arousal Conditions) and Erectile Dysfunction Therapy Areas, 2005 & 2012
- Figure 7.12 Comparative Analysis of Leading Dermatology Products, 2004-2012 (US$m)
- Figure 7.13 Comparative Analysis of Leading CNS Products, 2004-2012 (US$m)
- Figure 7.14 Comparative Analysis of Leading Contraceptives and Infertility Drug Products, 2004-2012 (US$m)
- Figure 7.15 Comparative Analysis of Leading Testosterone Replacement Therapies and Erectile Dysfunction Products, 2004-2012 (US$m)
- Figure 7.16 Key Alopecia Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
- Figure 7.17 Key Dermal Ageing Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
- Figure 7.18 Key Dermal Pigmentation Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
- Figure 7.19 Key Lipodermal Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
- Figure 7.20 Key Antidepressant Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
- Figure 7.21 Key Cognitive/Memory Impairment Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
- Figure 7.22 Key Addiction Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
- Figure 7.23 Key Sleep-Wake Promotion Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
- Figure 7.24 Key Contraception Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
- Figure 7.25 Key Infertility Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
- Figure 7.26 Key Testosterone Replacement Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
- Figure 7.27 Key Erectile Dysfunction and Premature Ejaculation Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
- Figure 7.28 Key Female Sexual Dysfunction Drug Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005
- Figure 7.29 Top Ten Prospects in the Antiageing and Life Enhancement Development Pipeline, 2005